Pfizer Inc. will feature the latest innovations from its expanding hematology and breast cancer lines at the American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13). Through over 100 abstracts, which include 13 oral presentations and four poster highlights, the company will exhibit data on both its approved treatments and emerging therapies for blood and breast cancers, as well as rare blood diseases.
“Our significant presence at ASH and SABCS affirms Pfizer’s strong commitment to scientific advancement for individuals with blood disorders and breast cancer,” stated Chris Boshoff, the chief oncology officer and executive vice president of Pfizer. “We are thrilled to showcase the latest insights for our essential approved medications, including Adcetris, Elrexfio, and Ibrance, which are pivotal in their respective treatments. Additionally, we look forward to unveiling new findings in hemophilia and from our burgeoning pipeline of pioneering therapy candidates for both blood and breast cancers, as well as upcoming data on combination strategies using our primary scientific platforms.”
**Prominent ASH Presentations:**
Over 75 company-sponsored, investigator-sponsored, and collaborative research papers will be shared at ASH. This includes updated analyses from the crucial ECHELON-3 trial, demonstrating the clinical advantages of Adcetris (brentuximab vedotin) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). New information on Elrexfio (elranatamab-bcmm) for relapsed/refractory multiple myeloma (RRMM) will be shared from the pivotal MagnetisMM-3 trial, alongside phase 1 combination data from the MagnetisMM-20 trial. Pfizer will also provide updates on its expanding hematology-oncology pipeline, featuring next-generation CD30 antibody-drug conjugates and distinct molecules, as well as debuting combination data for SEA-CD70 in high-risk myelodysplastic syndromes.
Moreover, Pfizer will offer results from its roster of investigational and approved drugs in benign hematology.
– **Adcetris:** Additional analyses of the phase 3 ECHELON-3 trial will spotlight the robustness and consistent advantages of Adcetris, paired with lenalidomide and rituximab for patients with relapsed/refractory DLBCL, including older patients, those resistant to recent treatments, and those previously treated with CAR-T therapy. These results emphasize an OS benefit over lenalidomide and rituximab plus placebo for patients with at least two prior treatment lines. Updated two-year follow-up data from a phase 2 trial testing a novel combination of Adcetris, nivolumab, doxorubicin, and dacarbazine in early-stage classical Hodgkin lymphoma (cHL) reveal promising efficacy and safety.
– **Elrexfio:** A post hoc review of the phase 2 MagnetisMM-3 trial shows continued deep responses over a lengthy follow-up of nearly three years, even with monthly dosing reductions in RRMM. Ongoing phase 1b MagnetisMM-20 trial data indicates beneficial clinical efficacy and predictable safety signals for Elrexfio in combination with carfilzomib and dexamethasone after an average of two prior treatment lines (range: one to three).
– **SEA-CD70 (PF-08046040):** For the first time, promising preliminary results are shared from the ongoing phase 1 study with PF-08046040, also known as SEA-CD70, a monoclonal antibody targeting CD70 designed to enhance effector function. Data from the combination dose-optimization cohort with azacitidine in high-risk myelodysplastic syndromes (MDS) will be presented. SEA-CD70 aims to be a top-tier foundational treatment, either alone or in combination for myeloid cancers.
**Noteworthy SABCS Presentations:**
Data from 30 company-sponsored, investigator-sponsored, and collaborative study abstracts will be exhibited at SABCS, including nine real-world evaluations endorsing Ibrance (palbociclib) as a first-line standard-of-care therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). The company will also provide fresh data from its broadening array of cutting-edge, next-gen therapy candidates poised to meet crucial unmet patient needs across all breast cancer stages and subtypes, including new and updated phase 1 data for atirmociclib, vepdegestrant, and the innovative KAT6 inhibitor, PF-07248144.
– **Ibrance:** In P-VERIFY, the largest real-world comparative overall survival analysis of first-line CDK4/6 inhibitors plus aromatase inhibitor (AI) therapy in HR+/HER2- MBC, comparable overall survival rates were found across CDK4/6 inhibitor groups at 12, 24, and 30 months.